Possemis, Nina http://orcid.org/0000-0002-7279-4052
Caldenhove, Stéphanie http://orcid.org/0000-0002-5058-5380
Sambeth, Anke http://orcid.org/0000-0002-3654-9383
Blokland, Arjan http://orcid.org/0000-0002-4337-7479
Article History
Received: 16 November 2023
Accepted: 22 February 2024
First Online: 4 March 2024
Declarations
:
: Informed consent was obtained from all individual participants included in the study.
: AB and AS have a proprietary interest in the PDE4 inhibitor roflumilast for the treatment of cognitive impairment.